טוען...
New developments in the treatment of multiple myeloma – clinical utility of daratumumab
Multiple myeloma is a clonal disorder of plasma cells that is currently considered incurable. CD38 is a 46 kDa type II transmembrane glycoprotein that is highly expressed on myeloma cells. Daratumumab is a first in-class human IgG1 monoclonal antibody that targets CD38, and has antimyeloma effects t...
שמור ב:
| הוצא לאור ב: | Biologics |
|---|---|
| Main Authors: | , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Dove Medical Press
2017
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5395289/ https://ncbi.nlm.nih.gov/pubmed/28442888 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/BTT.S97633 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|